Interpace Biosciences, Inc. (IDXG)

Interpace Biosciences Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	5	5	4	31	13	19
Market Cap Growth	26.14%	5.78%	-85.73%	144.16%	-32.46%	-16.86%
Enterprise Value	13	12	16	41	15	24
PE Ratio	5.79	5.81	-0.75	-2.09	-0.48	-0.70
PS Ratio	0.13	0.12	0.14	0.75	0.39	0.78
PB Ratio	-0.41	-0.31	-0.07	-0.73	-0.43	1.44
P/FCF Ratio	2.47	1.40	-0.55	-3.40	-0.78	-0.98
P/OCF Ratio	2.06	1.23	-0.57	-3.54	-0.87	-0.99
EV/Sales Ratio	0.32	0.31	0.49	1.00	0.45	0.98
EV/EBITDA Ratio	3.60	3.22	-4.14	-5.05	-0.68	-1.17
EV/EBIT Ratio	4.62	4.40	-2.47	-3.05	-0.54	-0.97
EV/FCF Ratio	6.05	3.72	-1.96	-4.55	-0.91	-1.23
Debt / Equity Ratio	-0.63	-0.64	-0.26	-0.32	-0.16	0.54
Debt / EBITDA Ratio	2.91	2.92	-4.26	-1.68	-0.22	-0.35
Debt / FCF Ratio	4.88	3.37	-2.01	-1.51	-0.29	-0.37
Quick Ratio	0.41	0.49	0.69	0.60	0.59	0.72
Current Ratio	0.50	0.59	0.85	0.78	0.77	0.95
Asset Turnover	2.96	3.09	1.99	1.08	0.71	0.35
Interest Coverage	4.05	2.79	-3.81	-12.76	-48.37	-54.39
Return on Equity (ROE)	-6.29%	-5.30%	9.30%	34.76%	90.09%	-204.51%
Return on Assets (ROA)	7.57%	6.16%	-36.70%	-38.37%	-57.36%	-38.58%
Return on Capital (ROIC)	-73.61%	-70.20%	8.17%	40.89%	109.10%	-118.94%
Earnings Yield	17.21%	17.20%	-133.07%	-47.74%	-207.11%	-142.23%
FCF Yield	40.55%	71.19%	-181.83%	-29.37%	-127.69%	-101.91%
Buyback Yield / Dilution	-1.76%	-2.97%	-2.49%	-2.63%	-7.55%	-33.03%
Total Shareholder Return	-1.76%	-2.97%	-2.49%	-2.63%	-7.55%	-33.03%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.